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Introduction
Diabetes  mellitus,  characterized  by  chronic 
hyperglycemia  and  dyslipidemia,  is  a  deleterious 
metabolic complication and is estimated to afflict 5-7% 
of  the  world  population.
1Hyperglycemia  and 
dyslipidemia are the  two debilitating concomitants  of 
diabetes  which  play  a  key  role  in  creating  the 
secondary disorders such as macro and micro vascular 
complications.
2 
The Framingham Heart Study found that dyslipidemia 
was very common in adults with diabetes, characterized 
by high levels of triglyceride and total cholesterol and 
low levels of HDL-C.
3 This pattern befalls commonly 
in both type 1 and type 2 diabetes mellitus, reflecting 
the  basic  pathogenic  state  of  insulin  secretion 
insufficiency or lack of effective action due to insulin 
resistance. Moreover plasma lipoprotein levels reflect 
increased number not only of LDL, but also of IDL and 
VLDL particles.
4 This general pattern was shown to be 
strongly  related  to  the  severity  of  atherosclerosis.
5  A 
majority of diabetic patients suffer from dyslipidemia 
that  is  related  to  insulin  resistance.  Dyslipidemia 
precedes the clinical diagnosis of diabetes by years as a 
part of diabetic complications and metabolic syndrome 
and  it  is  so  deeply  involved  in  its  pathogenesis.
6 
Epidemiological  investigations  demonstrated  that 
increased  levels  of  LDL  cholesterol  and  non-HDL 
cholesterol,  besides  decreased  level  of  HDL 
cholesterol, were strong risk factors for atherosclerosis 
in diabetic patient.
7-9 Chronic hyperglycemia can also 
lead  to  dysfunction  and  failure  of  various  organs, 
including  the  heart,  kidneys,  eyes,  nerves,  and  blood 
vessels, and creates a huge economic burden pertaining 
to the management of diabetic complications.
10 
The  current  medical  nutrition  therapy  of  diabetes 
mellitus  includes  diet,  exercise,  various  oral 
antidiabetic  drugs  and  insulin  therapy.
11  The  modern 
oral  hypoglycemic  agents  (such  as  biguanides, 
sulphonylureas  and  α-glucosidase  inhibitors),  and 
insulin have characteristic of adverse effects, including 
hypoglycemia,  dyslipidemia,  lactic  acidosis, 
hepatotoxicity,  hypertension,  frequent  diarrhea,  and 
hypercoagulability other than economic expenses.
12 
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Purpose:  Resveratrol  a  natural  polyphenolicstilbene  derivative  has  wide  variety  of 
biological  activities.  There  is  also  a  large  body  of  evidence  demonstrating  positive 
effect  of  resveratrol  in  treatment  of  various  metabolic  complications  including 
metabolic syndrome, obesity, diabetes and dyslipidemia in adults. The purpose of this 
study  was  to  investigate  anti-hyperglycemic  and  anti-dyslipidemic  effects  of 
resveratrol.  Methods:  We  used  40  diabetic  streptozotocinWistar  rats.  Rats  were 
randomly  divided  into  5  treatment  groups  (n=8  in  each)  including  normal  control, 
normal  treated  with  resveratrol,  diabetic  control,  diabetic  treated  with  vanadium  , 
diabetic  treated  with  resveratrol  .  Resveratrol  (25  mg/kgbw)  and  vanadate  (0.2 
mg/kgbw) was orally gavaged for 40 days and blood samples were directly collected 
from  heart.  Results:  Diabetic  rats  treated  with  resveratrol  in  comparison  to  control 
diabetic  rats  demonstrated  a  significant  (p  =  0.001)  decline  in  serum  glucose 
concentration,  and  high  plasma  concentrations  of  total  cholesterol  and  LDL-c  were 
reduced (p = 0.031, p = 0.004 respectively). Furthermore, body weight loss trend that 
observed in diabetic rats alleviated by resveratrol and vanadate. However triglyceride, 
VLDL-c and HDL-c levels did not changed significantly. Conclusion: In conclusion 
Resveratrol  ameliorated  dyslipidemia  and  hyperglycemia  in  diabetic  rats.  However 
further investigations in peculiar human studies are required. 
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Therefore, concerning the high prevalence of diabetes 
in  the  worldwide  and  mentioned  side  effects  of  its 
current drugs, there is a necessity for novel therapies 
which  are  effective  with  minimal  adverse  events.
13 
Herbal  medicines  and  their  active  compounds 
possessed  these  properties.  Resveratrol  (3,  5,  4-
trihydroxystilbene), which have been getting increasing 
attention  lately,  is  one  of  the  phytochemicalsfound 
particularly  in  grapes  and  mulberries.
14Approximately 
5-10%  of  the  biomass  of  grape  skins  accounts  for 
resveratrol.
15 Resveratrol is also a component of Ko-jo-
kon,  an  oriental  folk  medicine  used  to  treat  lipid 
disorders.
10 The in vitro and in vivo studies confirmed 
the  protective  properties  of  resveratrol  and  its 
accumulation  in  red  wine  had  led  the  scientists  to 
consider  that  this  is  the  competent  substance  for  the 
‘‘French paradox’’.
16 Additionally, resveratrol has been 
reported  to  involve  in  numerous  cellular  responses 
including  cell  cycle  arrest,  apoptosis  and 
differentiation, and has anti-inflammatory, anti-cancer, 
anti-leukemic,  antiviral,  and  neuroprotective 
properties.
16-20  Several important human enzymes that 
are  involved  in  carcinogenesis  could  be  inhibited  by 
resveratrol,  including  ribonucleotidereductase  and 
cytochrome  P450.
21,22  The  antioxidant  role  of 
resveratrol also has been reported which can reduce the 
risk  of  undergoing  cardiovascular  disease  (CVD), 
likely through its prevention of low density lipoprotein 
oxidation and modulation of lipid metabolism, as well 
as  inhibition  of  eicosanoid  synthesis  and  platelet 
aggregation.
23-25 Since then, it has been investigated as 
an effective treatment for metabolic complications.
26 
It is also speculated that resveratrol could be effective 
in  controlling  of  hyperglycemia  and  dyslipidemia  in 
diabetes.  However,  no  systematic  studies  exist  in  the 
literature  on  the  effect  of  resveratrol  in  experimental 
models  of  diabetic  hyperglycemia  and  dyslipidemia. 
Therefore, the present study was aimed to investigate 
the  antihyperglycemic  and  antihyperlipidemic  effects 
of resveratrol in streptozotocin induced diabetic rats.  
 
Materials and methods 
Chemicals  
Resveratrol was purchased from Nutrabio Co.  (USA) 
and  streptozotocin  (STZ)  was  procured  from  Sigma-
Aldrich Chemical Co. (Steinheim, Germany). All other 
chemicals  used  in  this  study  were  of  the  analytical 
grade,  preserved  under  standard  situation  and  were 
provided from standard commercial suppliers. 
 
Experimental animals 
Male albino rats of Wistar strain weighing 200-220 g 
and 6 week-old were chosen as animal model for this 
study,  obtained  from  Physiology  Research  Center  of 
Ahvaz  JundiShapour  University  of  Medical  Sciences 
and maintained in clean, polypropylene cages and fed 
ad libitum standard chow and water. Before experiment 
initiation,  the  rats  were  quarantined  for  2  weeks  in 
order  to  environmental  and  trainer  handling 
acclimatization.  All  animal  manipulations  were 
performed  in  the  morning  to  minimize  the  effects  of 
circadian rhythm. The animal experimental design was 
precisely  in  accordance  with  the  ethical  norms 
approved  by  Animal  Care  and  Use  Committee  of 
Ahvaz  JundiShapour  University  of  Medical  Sciences, 
Ahvaz, Iran. 
 
Induction of experimental diabetes 
Diabetes  was  induced  by  a  single  intraperitoneal 
injection  of  streptozotocin  (STZ)  (50  mg/kg  body 
weight) dissolved in 0.1 M of cold citrate buffer (pH= 
4.5), after rats were 12 h fasted.
27 Due to capability of 
STZ  to  induce  fatal  hypoglycemia  as  a  result  of 
massive  pancreatic  insulin  release,  the  rats  were 
supported for the next 24 h with 10% glucose solution 
after  STZ  administration  to  hinder  hypoglycemia. 
Neither  death  nor  any  other  contrary  effect  was 
observed.  After  a  week  for  the  evolution  and 
exacerbation  of  diabetes,  rats  with  fasting  blood 
glucose  concentration  over  than  250  mg/dl  were 
selected for the experimental model of diabetes. 
 
Experimental design 
Forty  rats  were  divided  randomly  into  five  groups 
(n=8) and treated as follows: 
Group  1:  Normal  control  rats  (N);  Group  2:  Normal 
rats treated with resveratrol (25 mg/kgbw/d) (N +RV); 
Group 3: Diabetic rats (DM); Group 4: Diabetic rats 
treated with resveratrol (25 mg/kg bw/d) (DM + RV); 
Group  5:  Diabetic  rats  treated  with  vanadate  (0.2 
mg/kgbw/d)  as  positive  control  (DM  +  VA). 
Resveratrol and vanadate was given by oral gavage and 
the  treatments  lasted  for  40  consecutive  days.  Food 
intake and body weight of the animals were monitored 
twice a week. At the end of the study, the rats were 
fasted  overnight  with  free  access  to  water, 
anaesthetized  with  light  ether  and  sacrificed.  Blood 
samples  were  directly  collected  from  heart.  Serum 
glucose, triglycerides (TG), total cholesterol (TC) and 
high density lipoprotein (HDL) levels were determined 
enzymatically  using  standard  methods  to  confirm  the 
anti-hyperglycemic and anti-dyslipidemic properties of 
resveratrol.  Low  density  lipoprotein  (LDL)  level  was 
calculated by Friedwald formula. 
 
Statistical analysis 
The  results  were  expressed  as  mean  ±  SD.  The 
statistical  significance  was  evaluated  by  independent 
sample  t-test  and  one-way  analysis  of  variance 
(ANOVA)  using  the  SPSS  (version  17.0)  program 
followed by Tuky. Values were considered statistically 
significant when p < 0.05. 
Results 
Table 1 illustrates the effects of resveratrol on serum 
glucose levels in experimental groups. As it is shown in 
the table 1, oral administration of 25 mg/kg resveratrol 
in  normal  rats  did  not  change  glucose  levels  
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significantly in comparison to the normal control group 
(p=0.365). 
The  streptozotocin  induced  diabetic  rats  showed  a 
significantly higher serum glucose levels than those of 
normalcontrol rats, whereas the elevated serum glucose 
level was significantly reduced  in diabetic rats  orally 
administrated with 5 mg/kg resveratrol (p = 0.001). In 
Vanadate  treated  diabetic  rats  (with  a  dose  of  0.2 
mg/kgbw/d), reduced glycemia occurred after 40 days 
of experiment in comparison to STZ induced diabetic 
control rats (p = 0.000). 
The  effects  of  oral  administration  of  resveratrol  on 
serum  levels  of  TG,  TC,  LDL-C  and  HDL-C      are 
shown in Figure 1, respectively. As it is obvious in the 
figure 1, diabetic control group had significantly higher 
concentrations  of  triglyceride,  total  cholesterol  and 
LDL-C, as well as, lower concentration of HDL-C than 
those  of  normal  control  group  (p<0.05).  The  present 
data  also  indicated  that  the  serum  concentrations  of 
total  cholesterol  and  LDL-C  were  decreased 
significantly (p = 0.031, p = 0.004, respectively) after 
oral  administration  of  resveratrol  in  diabetic  rats  but 
triglyceride  and  HDL-C  levels  did  not  changed 
significantly when compared to diabetic control group 
(p> 0.05). In normal group, the effect of resveratrol (25 
mg/kg)  on  lipid  profiles  was  not  statistically 
significant. 
In  addition  no  significant  change  in  triglyceride  and 
cholesterol  concentration  was  observed  in  Vanadate 
treated  rats  in  comparison  to  diabetic  control  group 
(p>0.05)  whereas  LDL-c  decreased  and  HDL-c 
increased  significantly  (p  =0.032  and  p=0.041 
respectively). 
Figure  2  depicts  body  weight  changes  in  different 
groups during present study. Diabetes induction in DM 
group  caused  deleterious  inhibition  of  normal  weight 
gain  trend  that  was  proceeding    in  N  and  N  +  RV 
groups.  Moreover  Resveratrol  and  Vanadate 
administration  ameliorated  consequent  body  weight 
loss of STZ induced diabetes. 
 
Table 1. Effect of the orally administered resveratroland vanadate on serum glucose levels in experimental groups
 a 
Groups  glucose (mg/dl)  Pa  Pb  Pc  Pd 
Normal control  122.1±69.9  _  0.365  0.000  0.052 
Normal + Resveratrol(25mg/kg)  159.8±42.8  0.365  _  0.000  0.310 
Diabetic control  367±154.7  0.000  0.000  _  0.001 
Diabetic + Resveratrol(25mg/kg)  202.1±60  0.052  0.310  0.001  _ 
Diabetic + vanadate(0.2mg/kg)  174.1±28.5  0.215  0.738  0.000  0.500 
aAll values are expressed as mean ± SD (n=8). One way ANOVA test was used for statistical significance assessment. 
Pa indicates P value between Normal control and remaining groups. 
Pb indicates P value between Normal resveratrol treated and remaining groups. 
Pc indicates P value between diabetic control and remaining groups. 
Pd indicates P value between diabetic resveratrol treated diabetic and remaining rats. 
 
 
 
Figure 1. Effect of the orally administered resveratrol and vanadate on serum levels of lipids in experimental groups
 
Data shown as mean±SD 
* means p<0.05 in comparison with diabetic control group  
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Figure 2. Effect of orally administered resveratrol and vanadate on body weight changes in experimental groups
 
Discussion 
Diabetes  mellitus  is  a  metabolic  disturbance  by  a 
characteristic of hyperglycemia resulting from defects 
in insulin secretion, insulin action or both
1, and is also 
concomitant  with  disorders  in  glucose  and  lipid 
metabolism.
2  Numerous  herbal  medicines  have  been 
reported  to  have  hypoglycemic  and  hypolipidemic 
impacts in diabetes. Resveratrol is a substance largely 
found  in  the  skins  of  red  grapes  and  it  has  gained 
scientists’  interest  because  of  having  many 
advantageous effects on promoting health and disease. 
Therefore, in this study we investigated its potentiality 
to improve hyperglycemia and hyperlipidemia in STZ-
induced diabetic rats. 
The elevated blood glucose level in diabetic rats was 
significantly  reduced  in  resveratrol  treated  group. 
These  findingshave  been  corroborated  by  Miuraet  al. 
research
28, suggesting possible recovery mechanism of 
resveratrol  on  the  remnant  β-cells  functionality  and 
partially  improved  dyslipidemia  in  experimental 
diabetic animals. 
Diabetes is associated with profound complications of 
plasma  lipid  and  lipoprotein  profile.  Many  other 
researchers  have  reported  controversial  effect  of 
resveratrol  on  lipid  profile  in  experimental 
animals.Rivera  et  al.  reported  triglyceride  lowering 
properties  of  resveratrol  with  a  dosage  of  10  mg/kg 
administered  intragastrically,  for  8  weeks  of  study, 
while this study demonstrated no significant reduction 
in  triglyceride  level.  It  has  been  proposed  that  some 
favourable  effects  of  resveratrol  result  from 
phosphorylation/activation of 5′-AMP-activated protein 
kinase  (AMPK).  AMPK  inhibits  acetyl-CoA 
carboxylase  elevating  oxidation  of  fatty  acids  when 
activated and suppress their synthesis. A considerable 
increase  in  AMPK  activity  was  reported  in  obese 
Zucker rats too.
29 In another study Do et al. examined 
long  term  effect  of  resveratrol  supplementation  on 
suppression  of  atherogenic  lesion  formation  and 
cholesterol synthesis and LDL-C oxidation in apo  E-
deficient mice. The concentration of LDL-C and total-
cholesterol  was  significantly  decreased  in  the 
resveratrol treated groups compare to the control group. 
Besides  the  plasma  HDL-C  concentration  was 
significantly augmented.
30  About  the  mechanism  Kim 
S.  and  Do  G.suggested  that  resveratrol  may  hinder 
adipogenesis  plausibly  through  suppression  of  the 
galanin-mediated signaling pathway, pro-inflammatory 
signaling cascades and cytokine production in adipose 
tissue  of  mice  fed  a  high  fat  diet.
31However  in  our 
study  HDL-C  did  not  change  significantly  despite 
reduction in LDL-C and total-cholesterol levels. 
Interestingly,  in  our  studies,  in  spite  of  the  fact  that 
body weight loss occurred in diabetes induced group, 
resveratrol  alleviated  detrimental  effects,  besides 
facilitating weight gain. However other studies reported 
that resveratrol reduce body weight gain in rats
32 and 
mice
33fed  a  high-fat  diet  (HFD).  Lagouge  et  al. 
indicated that 0.4% resveratrol supplementation for 15 
weeks  significantly  decreases  body  weight  gain  and 
visceral  fat-pad  weights  in  HFD-fed  mice.The 
mechanism by means of that resveratrol exerts positive 
effects  supposedly  is  related  to  induction  of  genes 
expression for oxidative phosphorylation. Multiple data 
imply  that  activation  of  an  NAD
+-dependent  protein 
deacetylase,  Sirt1,  is  pivotal  for  resveratrol  action.
33 
Nevertheless, in the other experiments this effect was 
not observed.
34-35 Resveratrol (10 mg/kg body weight;  
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administered for 8 weeks) suggested not to be efficient 
in reducing body weight gain in obese Zucker rats.
29 
At  the  end  our  results  show  that  daily  chronic 
administration of 5 mg/kgbw of resveratrol ameliorated 
dyslipidemia  and  hyperglycemia  in  the  experimental 
model diabetic rats. Our results approximately certify 
the beneficial effects of resveratrol in the treatment of 
modifications  involved  in  metabolic  disturbances 
including glucose, LDL-C and total cholesterol. 
29, 36,37 
Nevertheless, there are other investigations suggesting 
no  positive  effect  of  resveratrol  on  dyslipidemia  and 
hyperglycemia.
38 
In  conclusion,  since  resveratrol  possesses  significant 
hypoglycemic potentiality, it may be interceded on the 
treatment of diabetes. Studies in the last few years infer 
that resveratrol functions numerous beneficial effects in 
metabolic  disturbances  and  diabetes,  thereby  may  be 
beneficial  in  prevention  and  treatment  of  many  other 
diseases.  However,  further  studies  are  required  to 
distinct discrepancies in the literature. Besides, despite 
evidences  representing  promising  effects  in  rodents, 
human  studies  are  deficient  and  either  therapeutic  or 
preventive values of resveratrol in humans still remain 
to be elucidated. 
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